APA Handbook of Psychopharmacology (APA Handbooks in Psychology®)

The APA Handbook of Psychopharmacology is designed as a comprehensive library reference that captures current research on pharmacotherapy strategies, as an informative guide for educators and students to strengthen their understanding of the scientific and professional issues associated with the field, and as an invaluable desk reference for both researchers and practicing clinicians. The 33 chapters cover fundamental principles of pharmacology and psychopharmacology; psychopharmacology for the treatment of emotional and behavioral conditions; and issues around training, policy, and industry.

About the Editor-in-Chief
 
Suzette M. Evans, PhD, is a psychologist trained in biopsychology at The University of Chicago and in behavioral pharmacology at the Johns Hopkins University School of Medicine. She is currently a professor of clinical neurobiology (in psychiatry) at the Columbia University Vagelos College of Physicians and Surgeons and research scientist VI at the New York State Psychiatric Institute. She has been a member of the American Psychological Association (APA) and Division 28 (Psychopharmacology and Substance Abuse) since 1992. She served as president of Division 28 in 2007 and served as a member of the APA Board of Convention Affairs from 2011 to 2014. She is also a recent past editor of the APA journal Experimental and Clinical Psychopharmacology (2011–2017).
     Dr. Evans has more than 100 publications and 30 years of research experience that span preclinical research with laboratory animals, human laboratory research, and clinical treatment research in substance abuse. Over the past 25 years Dr. Evans has received continuous research funding, primarily from the National Institute on Drug Abuse. Much of her research has used controlled laboratory procedures in humans to examine the acute behavioral and reinforcing effects of drugs of abuse, including alcohol, cannabis, and cocaine. Her focus is identifying potential behavioral and neurobiological markers of vulnerability to identify high-risk individuals before they transition from casual recreational use to problematic drug use. Several of these factors include stress, impulsivity, and decision making. Moreover, she has been at the forefront of exploring the role of sex as a biological variable. Much of her past and current research focuses on examining potential differences between males and females, including hormonal influences across the menstrual cycle.